Our Pipeline

Exelixis has a diverse portfolio of small molecule and biologics programs moving forward, covering a broad range of targets and therapeutic modalities. We are committed to further enhancing our pipeline and expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians.

Asset / Program Name (Mechanism)
Development Status
Phase /
Development Status
  • Discovery/
    Preclinical
  • IND
  • Phase 1a
  • Phase 1b
  • Phase 2/3
Cabozantinib (Multi-TKI targeting MET/VEGFR/AXL/RET)
Multi-TKI targeting MET/VEGFR/AXL/RET
  • Phase 2/3 CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023
CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023
  • Phase 2/3 COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023
Zanzalintinib (XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER)
XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER
  • Phase 2/3 STELLAR-304 (nccRCC)
STELLAR-304 (nccRCC)
  • Phase 2/3 STELLAR-303 (CRC)
STELLAR-303 (CRC)
  • Phase 1b STELLAR-002 (Solid tumors)
STELLAR-002 (Solid tumors)
  • Phase 1b STELLAR-001 (Solid tumors)
STELLAR-001 (Solid tumors)
XB002 (Next-generation TF-targeting ADC)
Next-generation TF-targeting ADC
  • Phase 1a JEWEL-101 (Solid tumors)
JEWEL-101 (Solid tumors)
XL102 (Oral CDK7 inhibitor)
Oral CDK7 inhibitor
  • Phase 1a QUARTZ-101 (Solid tumors)
QUARTZ-101 (Solid tumors)
CBX-12 (Peptide-drug candidate)
Peptide-drug candidate
  • Phase 1a Option to acquire asset pending certain phase 1 results
Option to acquire asset pending certain phase 1 results
Cybrexa Therapeutics
ADU-1805 (SIRPα-targeting mAb)
SIRPα-targeting mAb
  • Phase 1a Option to acquire asset pending certain phase 1 results
Option to acquire asset pending certain phase 1 results
Sairopa
XB010 (Next-generation 5T4-targeting ADC)
Next-generation 5T4-targeting ADC
  • Discovery/
    Preclinical
XB014 (Bispecific antibody targeting PD-L1 + CD47)
Bispecific antibody targeting PD-L1 + CD47
  • Discovery/
    Preclinical
XB628 (Bispecific antibody targeting PD-L1 + NKG2A)
Bispecific antibody targeting PD-L1 + NKG2A
  • Discovery/
    Preclinical
XB371 (Next-generation TF-topoisomerase ADC)
Next-generation TF-topoisomerase ADC
  • Discovery/
    Preclinical
Invenra Collaboration Program (Non-disclosed)
Non-disclosed
  • Discovery/
    Preclinical
Aurigene Collaboration Programs (Non-disclosed)
Non-disclosed
  • Discovery/
    Preclinical
STORM Therapeutics Collaboration Program (ADAR1)
ADAR1
  • Discovery/
    Preclinical
Exelixis Discovery Programs (PKMYT1 inhibitors)
PKMYT1 inhibitors
  • Discovery/
    Preclinical
Biotherapeutics Program (AMHR2, ROR1/2, TF, DLL3)
AMHR2, ROR1/2, TF, DLL3
  • Discovery/
    Preclinical
Invenra, NBE Therapeutics, Catalent, GamaMabs, WuXi, Adagene, BioInvent and Ryvu Theraputics Collaborations

Additional undisclosed programs ongoing with Aurigene, Invenra, STORM Therapeutics and through internal Exelixis Discovery

  • ADAR1 = adenosine deaminase 1
  • ADC = antibody-drug conjugate
  • AMHR2 = anti-mullerian hormone receptor 2
  • CDK7 = cyclin-dependent kinase 7
  • CDK12 = cyclin-dependent kinase 12
  • CRC = Colorectal cancer
  • DLL3 = delta-like ligand 3
  • IND = Investigational New Drug application
  • MALT1 = mucosa associated lymphoid tissue lymphoma translocation gene 1
  • mCRPC = Metastatic castration-resistant prostate cancer
  • nccRCC = Non-clear cell renal cell carcinoma
  • NKG2A = natural killer cell receptor group 2A
  • OS = Overall survival
  • PFS = Progression-free survival
  • PKMYT1 = protein kinase, membrane associated tyrosine/threonine 1
  • RCC = Renal cell carcinoma
  • ROR1/2 = receptor tyrosine kinase like orphan receptor 1/2
  • SIRPα = signal regulatory protein alpha
  • TF = tissue factor
  • TKI = tyrosine kinase inhibitor

Other Partnered Programs

We are also advancing cancer treatment through collaborations.

Learn More